UNSPSC 51362102: Bromisoval or bromvalerylurea

This classification denotes a sedative and hypnotic with the molecular formula C6H11BrN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 469GW8R486, chemically known as urea, (2-bromo-3-methylbutyryl)- but generally known as bromisoval, which bears US NIH Compound Identifier 2447. European Medicines Agency schedules Bromisoval in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05916MIG.

UNSPSC 51362102 Bromisoval or bromvalerylurea is a Commodity code that nominally names a specific pharmaceutical sedative compound, but recent state and local procurement activity under this code shows no direct alignment with the code's stated scope. The three most recent opportunities posted under this code involve naloxone and drug deactivation systems, therapeutic pharmacy initiatives for direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products — none of which center on bromisoval or bromvalerylurea procurement. The code shows misclassification or data-integrity issues that weaken its utility for business development targeting the actual pharmaceutical categories being solicited.

Issuing bodies active under this code span a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP). Recent activity includes an IFB from Seminole County on June 30, 2026, due July 26, 2023, for naloxone and safe drug deactivation systems; an RFI from Texas HHS posted April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs; and an RFP from MMCAP posted January 20, 2026, due March 26, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon. Geographic activity centers on Florida, Texas, and the upper Midwest. The code exhibits sufficient recent activity to warrant close scrutiny of whether the classification reflects actual procurement intent or represents upstream tagging errors that would misdirect vendors away from the substantive pharmaceutical opportunities genuinely available under related codes.